|
1
|
Steeg PS: Metastasis suppressors alter the
signal transduction of cancer cells. Nat Rev Cancer. 3:55–63. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mohanam S, Sawaya R, McCutcheon I,
Ali-Osman F, Boyd D and Rao JS: Modulation of in vitro invasion of
human glioblastoma cells by urokinase-type plasminogen activator
receptor antibody. Cancer Res. 53:4143–4147. 1993.PubMed/NCBI
|
|
3
|
Rao JS: Molecular mechanisms of glioma
invasiveness: the role of proteases. Nat Rev Cancer. 3:489–501.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Davies B, Waxman J, Wasan H, Abel P,
Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F:
Levels of matrix metalloproteases in bladder cancer correlate with
tumor grade and invasion. Cancer Res. 53:5365–5369. 1993.PubMed/NCBI
|
|
5
|
Horikoshi M: Histone acetylation: from
code to web and router via intrinsically disordered regions. Curr
Pharm Des. 19:5019–5042. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gräff J and Tsai LH: Histone acetylation:
molecular mnemonics on the chromatin. Nat Rev Neurosci. 14:97–111.
2013.PubMed/NCBI
|
|
7
|
Mayo MW, Denlinger CE, Broad RM, Yeung F,
Reilly ET, Shi Y and Jones DR: Ineffectiveness of histone
deacetylase inhibitors to induce apoptosis involves the
transcriptional activation of NF-kappa B through the Akt pathway. J
Biol Chem. 278:18980–18989. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brochier C, Dennis G, Rivieccio MA,
McLaughlin K, Coppola G, Ratan RR and Langley B: Specific
acetylation of p53 by HDAC inhibition prevents DNA damage-induced
apoptosis in neurons. J Neurosci. 33:8621–8632. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sachweh MC, Drummond CJ, Higgins M,
Campbell J and Laín S: Incompatible effects of p53 and HDAC
inhibition on p21 expression and cell cycle progression. Cell Death
Dis. 4:e5332013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheung WL, Briggs SD and Allis CD:
Acetylation and chromosomal functions. Curr Opin Cell Biol.
12:326–333. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Van Lint C, Emiliani S and Verdin E: The
expression of a small fraction of cellular genes is changed in
response to histone hyperacetylation. Gene Expr. 5:245–253.
1996.PubMed/NCBI
|
|
12
|
Mitsiades CS, Mitsiades NS, McMullan CJ,
et al: Transcriptional signature of histone deacetylase inhibition
in multiple myeloma: biological and clinical implications. Proc
Natl Acad Sci USA. 101:540–545. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song J, Noh JH, Lee JH, et al: Increased
expression of histone deacetylase 2 is found in human gastric
cancer. APMIS. 113:264–268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shao Y, Gao Z, Marks PA and Jiang X:
Apoptotic and autophagic cell death induced by histone deacetylase
inhibitors. Proc Natl Acad Sci USA. 101:18030–18035. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marks PA, Richon VM, Miller T and Kelly
WK: Histone deacetylase inhibitors. Adv Cancer Res. 91:137–168.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McGarry LC, Winnie JN and Ozanne BW:
Invasion of v-Fos(FBR)-transformed cells is dependent upon histone
deacetylase activity and suppression of histone deacetylase
regulated genes. Oncogene. 23:5284–5292. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marks PA, Richon VM, Kelly WK, Chiao JH
and Miller T: Histone deacetylase inhibitors: development as cancer
therapy. Novartis Found Symp. 259:269–281. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vigushin DM, Ali S, Pace PE, et al:
Trichostatin A is a histone deacetylase inhibitor with potent
antitumor activity against breast cancer in vivo. Clin Cancer Res.
7:971–976. 2001.
|
|
19
|
Tarasenko N, Nudelman A, Tarasenko I, et
al: Histone deacetylase inhibitors: the anticancer, antimetastatic
and antiangiogenic activities of AN-7 are superior to those of the
clinically tested AN-9 (Pivanex). Clin Exp Metastasis. 25:703–716.
2008. View Article : Google Scholar
|
|
20
|
Bolden JE, Peart MJ and Johnstone RW:
Anticancer activities of histone deacetylase inhibitors. Nat Rev
Drug Discov. 5:769–784. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu LT, Chang HC, Chiang LC and Hung WC:
Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2
activation and cancer cell invasion. Cancer Res. 63:3069–3072.
2003.PubMed/NCBI
|
|
22
|
Hsu CH, Peng KL, Kang ML, et al: TET1
suppresses cancer invasion by activating the tissue inhibitors of
metalloproteinases. Cell Rep. 2:568–579. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang H, Liu Y, Bai F, et al: Tumor
development is associated with decrease of TET gene expression and
5-methylcytosine hydroxylation. Oncogene. 32:663–669. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Asrani K, Keri RA, Galisteo R, et al: The
HER2- and heregulin beta1 (HRG)-inducible TNFR superfamily member
Fn14 promotes HRG-driven breast cancer cell migration, invasion,
and MMP9 expression. Mol Cancer Res. 11:393–404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brown SA, Ghosh A and Winkles JA:
Full-length, membrane-anchored TWEAK can function as a juxtacrine
signaling molecule and activate the NF-kappaB pathway. J Biol Chem.
285:17432–17441. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grimaldi C, Pisanti S, Laezza C, et al:
Anandamide inhibits adhesion and migration of breast cancer cells.
Exp Cell Res. 312:363–373. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Albini A, Melchiori A, Santi L, Liotta LA,
Brown PD and Stetler-Stevenson WG: Tumor cell invasion inhibited by
TIMP-2. J Natl Cancer Inst. 83:775–779. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Baker AH, George SJ, Zaltsman AB, Murphy G
and Newby AC: Inhibition of invasion and induction of apoptotic
cell death of cancer cell lines by overexpression of TIMP-3. Br J
Cancer. 79:1347–1355. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jinga D, Stefanescu M, Blidaru A, Condrea
I, Pistol G and Matache C: Serum levels of matrix
metalloproteinases MMP-2 and MMP-9 and their tissue natural
inhibitors in breast tumors. Roum Arch Microbiol Immunol.
63:141–158. 2004.PubMed/NCBI
|
|
30
|
Sier CF, Kubben FJ, Ganesh S, et al:
Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are
related to the overall survival of patients with gastric carcinoma.
Br J Cancer. 74:413–417. 1996. View Article : Google Scholar
|
|
31
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
|
|
32
|
Taby R and Issa JP: Cancer epigenetics. CA
Cancer J Clin. 60:376–392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cai FF, Kohler C, Zhang B, Wang MH, Chen
WJ and Zhong XY: Epigenetic therapy for breast cancer. Int J Mol
Sci. 12:4465–4487. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Namdar M, Perez G, Ngo L and Marks PA:
Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA
damage and sensitizes transformed cells to anticancer agents. Proc
Natl Acad Sci USA. 107:20003–20008. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu T, Kuljaca S, Tee A and Marshall GM:
Histone deacetylase inhibitors: multifunctional anticancer agents.
Cancer Treat Rev. 32:157–165. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang X, Phillips DL, Ferguson AT, Nelson
WG, Herman JG and Davidson NE: Synergistic activation of functional
estrogen receptor (ER)-alpha by DNA methyltransferase and histone
deacetylase inhibition in human ER-alpha-negative breast cancer
cells. Cancer Res. 61:7025–7029. 2001.
|
|
37
|
Travaglini L, Vian L, Billi M, Grignani F
and Nervi C: Epigenetic reprogramming of breast cancer cells by
valproic acid occurs regardless of estrogen receptor status. Int J
Biochem Cell Biol. 41:225–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim SH, Kang HJ, Na H and Lee MO:
Trichostatin A enhances acetylation as well as protein stability of
ERalpha through induction of p300 protein. Breast Cancer Res.
12:R222010. View Article : Google Scholar
|
|
39
|
Henderson C, Mizzau M, Paroni G, Maestro
R, Schneider C and Brancolini C: Role of caspases, Bid, and p53 in
the apoptotic response triggered by histone deacetylase inhibitors
trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J
Biol Chem. 278:12579–12589. 2003. View Article : Google Scholar
|
|
40
|
Williams K, Christensen J, Pedersen MT, et
al: TET1 and hydroxymethylcytosine in transcription and DNA
methylation fidelity. Nature. 473:343–348. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kristensen LS, Nielsen HM and Hansen LL:
Epigenetics and cancer treatment. Eur J Pharmacol. 625:131–142.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hatziapostolou M and Iliopoulos D:
Epigenetic aberrations during oncogenesis. Cell Mol Life Sci.
68:1681–1702. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chik F and Szyf M: Effects of specific
DNMT gene depletion on cancer cell transformation and breast cancer
cell invasion; toward selective DNMT inhibitors. Carcinogenesis.
32:224–232. 2011. View Article : Google Scholar : PubMed/NCBI
|
